Are multiple sclerosis therapies safe in severe acute respiratory syndrome coronavirus 2 times?

Ferrara, Francesco; Porta, Raffaele La; Santilli, Priscilla; D'Aiuto, Vilma; Vitiello, Antonio

Ferrara, Francesco; Porta, Raffaele La; Santilli, Priscilla; D'Aiuto, Vilma; Vitiello, Antonio.

Ferrara F; Department of Pharmaceutical, Usl Umbria 1, Perugia, Italy.
Porta R; Department of Clinical Pathology, Asur Marche, Macerata, Italy.
Santilli P; Department of Pharmaceutical, Usl Umbria 1, Perugia, Italy.
D'Aiuto V; Department of Pharmaceutical, Usl Umbria 1, Perugia, Italy.
Vitiello A; Department of Pharmaceutical, Usl Umbria 1, Perugia, Italy.

Indian J Pharmacol ; 52(5): 441-442, 2020.

Article in English | MEDLINE | ID: covidwho-962438

Subject(s)

COVID-19; Immunosuppressive Agents/adverse effects; Immunosuppressive Agents/therapeutic use; Multiple Sclerosis/complications; Multiple Sclerosis/drug therapy; Pandemics; Humans; Lymphopenia/epidemiology; Lymphopenia/etiology; Risk

Fulltext

XML

PubMed Links

Search on Google

Full text: Available Collection: International databases Database: MEDLINE Main subject: Pandemics / COVID-19 / Immunosuppressive Agents / Multiple Sclerosis Type of study: Observational study / Prognostic study Topics: Long Covid Limits: Humans Language: English Journal: Indian J Pharmacol Year: 2020 Document Type: Article Affiliation country: Ijp.IJP_417_20

Similar

MEDLINE

LILACS

LIS

Fulltext

XML

PubMed Links

Search on Google